Forest and Adamas Announce NDA Filing for Fixed-Dose Alzheimer’s Drug

Forest Laboratories and Adamas Pharmaceuticals announced Forest’s submission of an NDA to the FDA for a fixed-dose combination of memantine HCl extended release and donepezil HCl for the treatment of moderate to severe dementia of the Alzheimer’s type.
MarketWatch